# EDGAR Filing Document

**Accession Number:** 0001837254
**File Stem:** 0001213900-25-094858
**Filing Date:** 2025-10
**Character Count:** 72872
**Document Hash:** 843a0c1ec549428fadea39b9d48dae98
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-094858.hdr.sgml**: 20251002

**ACCESSION NUMBER**: 0001213900-25-094858

**CONFORMED SUBMISSION TYPE**: S-1/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20251002

**DATE AS OF CHANGE**: 20251001

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Functional Brands Inc.
- **CENTRAL INDEX KEY:** 0001837254
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 854094332
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-284180
- **FILM NUMBER:** 251366011

**BUSINESS ADDRESS:**
- **STREET 1:** 8605 SANTA MONICA BLVD
- **CITY:** WEST HOLLYWOOD
- **STATE:** CA
- **ZIP:** 90069
- **BUSINESS PHONE:** 7789383367

**MAIL ADDRESS:**
- **STREET 1:** 8605 SANTA MONICA BLVD
- **CITY:** WEST HOLLYWOOD
- **STATE:** CA
- **ZIP:** 90069

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HT Naturals Corp.
- **DATE OF NAME CHANGE:** 20201218

As filed with the Securities and Exchange Commission on October 1, 2025.

**Registration No. 333-284180**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Amendment No. 12**

**to**

**FORM S-1**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

---

| |
|:---|
| &nbsp;&nbsp;**FUNCTIONAL BRANDS INC.**<br> (formerly HT Naturals Inc.) |
| &nbsp;&nbsp;**(Exact name of registrant as specified in its charter)** |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **325411** | **85-4094332** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification Number) |

---

**6400 SW Rosewood Street**

**Lake Oswego, Oregon 97035**

**(800) 245-8282**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Eric Gripentrog** 

**Chief Executive Officer**

**6400 SW Rosewood Street**

**Lake Oswego, Oregon 97035**

**(800) 245-8282**

(Names, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***

---

| | |
|:---|:---|
| **Ross D. Carmel, Esq.**<br> **Barry P. Biggar, Esq.** <br> **Sichenzia Ross Ference Carmel LLP** <br> **1185 Avenue of the Americas, 31<sup>st</sup> Floor**<br> **New York, NY 10036**<br> **(212) 930-9700** | **Eric Gripentrog**<br> **Tariq Rahim**<br> **Functional Brands Inc.**<br> **6400 SW Rosewood Street**<br> **Lake Oswego, Oregon 97035**<br> **(800) 245-8282** |

---

Approximate date of commencement of proposed sale to the public: **As soon as practicable after this Registration Statement becomes effective.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.**

***EXPLANATORY NOTE***

 ****

Functional Brands Inc. is filing this Amendment No. 12 (this "Amendment ") to the Registration Statement on [Form S-1](https://www.sec.gov/Archives/edgar/data/1837254/000121390025002120/ea0226997-s1_functional.htm) (Registration No. 333-284180), originally filed on January 8, 2025, and as amended from time to time (the "Registration Statement"), as an exhibits-only filing. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted.

No additional securities are being registered under this Amendment . All applicable registration fees were previously paid.

**Item 16. Exhibits**

(a) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1\*\*\* | [Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex3-1_function.htm) |
| 3.2\*\*\* | [Amended and Restated Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex3-2_function.htm) |
| 3.3\*\*\* | [Bylaws of Functional Brands Inc.](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex3-3_function.htm) |
| 3.4\*\*\* | [Amendment Name Change](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex3-4_function.htm) |
| 3.5\*\*\* | [Cert of Amendment Increase Authorized Shares](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex3-5_function.htm) |
| 3.6\*\*\* | [Cert of Amendment Reverse Split and Increase of authorized](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex3-6_function.htm) |
| 3.7\*\*\* | [Consent Resolution – Reverse Split](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex3-7_function.htm) |
| 3.8\*\*\* | [Form (Revised) of Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Share](https://www.sec.gov/Archives/edgar/data/1837254/000121390025089355/ea025801401ex3-8_function.htm) |
| 3.9\*\*\* | [Form (Revised) of Certificate of Designation, Preferences and Rights of the Series B Convertible Preferred Share](https://www.sec.gov/Archives/edgar/data/1837254/000121390025089355/ea025801401ex3-9_function.htm) |
| 4.1\*\*\* | [Specimen Common Stock Certificate](http://www.sec.gov/Archives/edgar/data/1837254/000121390025013149/ea023094101ex4-2_functional.htm) |
| 4.2\*\*\* | [Form of Placement Agent's Warrant](https://www.sec.gov/Archives/edgar/data/1837254/000121390025075072/ea025255301ex4-2_function.htm) |
| 4.3\*\*\* | [Amendment to the Placement Agent's Warrant](http://www.sec.gov/Archives/edgar/data/1837254/000121390025084203/ea025559001ex4-3_function.htm) |
| 5.1\* | [Opinion (Revised) of Sichenzia Ross Ference Carmel LLP](ea025978501ex5-1_function.htm) |
| 10.1\*\*\* | [License Agreement, dated July 7, 2021, between Trailer Park Boys Incorporated and Hemptown Organics Corp.](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-1_function.htm) |
| 10.2\*\*\* | [Amendment to the License Agreement, dated August 16, 2023, between Trailer Park Boys Incorporated and Hemptown Organics Corp.](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-2_function.htm) |
| 10.3\*\*\* | [Agreement, dated January 20, 2023, between HS Wholesale and Hemptown Naturals, Inc.](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-3_function.htm) |
| 10.4\*\*\* | [Asset Purchase Agreement dated June 28, 2019](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-4_function.htm) |
| 10.5\*\*\* | [Amendment No. 1 to the Asset Purchase Agreement dated November 30, 2021](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-5_function.htm) |
| 10.6\*\*\* | [Amendment No. 2 to the Asset Purchase Agreement dated May 16, 2022](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-6_function.htm) |
| 10.7\*\*\* | [Trademark Assignment Agreement dated July 11, 2019](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-7_function.htm) |
| 10.8\*\*\* | [Domain Names Transfer Agreement dated July 11, 2019](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-8_function.htm) |
| 10.9\*\*\* | [Assignment of Intangible Assets dated July 11, 2019](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-9_function.htm) |
| 10.10\*\*\* | [First Amended Forbearance Agreement dated December 27, 2022](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-10_function.htm) |
| 10.11\*\*\* | [Employment Agreement, effective March 11, 2025, between, Functional Brands Inc. and Eric Gripentrog](http://www.sec.gov/Archives/edgar/data/1837254/000121390025084203/ea025559001ex10-11_function.htm) |
| 10.12\*\*\* | [Employment Agreement, dated April 1, 2023, between HTO Holdings Inc., Functional Brands Inc. and Hemptown Organics Corp., and Tariq Rahim](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-12_function.htm) |
| 10.13\*\*\* | [ISO Certification - Purity Labs](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-13_function.htm) |
| 10.14\*\*\* | [Kirkman Certification validation from Purity](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-14_function.htm) |
| 10.15\*\*\* | [Testing Standards - The Forum](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-15_function.htm) |
| 10.16\*\*\* | [Schedule A to the Asset Purchase Agreement (Warranty Bill of Sale)](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-16_function.htm) |
| 10.17\*\*\* | [iHerb Inc agreement - Kirkman](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-17_function.htm) |
| 10.18\*\*\* | [Amendment to License Agreement with the Trailer Park Boys 9/25/2024](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-18_function.htm) |
| 10.19\*\*\* | [Fourth Amended Forbearance](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex10-19_function.htm) |
| 10.20\*\*\* | [Confession of Judgement](https://www.sec.gov/Archives/edgar/data/1837254/000121390025049411/ea024336701ex10-20_fun.htm) |
| 10.21\*\*\* | [Sixth Amended Forbearance](http://www.sec.gov/Archives/edgar/data/1837254/000121390025084203/ea025559001ex10-21_function.htm) |
| 10.22\*\*\* | [Seventh Amended Forbearance](http://www.sec.gov/Archives/edgar/data/1837254/000121390025084203/ea025559001ex10-22_function.htm) |
| 10.23\*\*\* | [Form of Securities Purchase Agreement](https://www.sec.gov/Archives/edgar/data/1837254/000121390025075072/ea025255301ex10-23_function.htm) |
| 10.24\*\*\* | [Form of Lock up](https://www.sec.gov/Archives/edgar/data/1837254/000121390025075072/ea025255301ex10-24_function.htm) |
| 10.25\*\*\* | [Marketing Services Agreement, dated July 23, 2025, between the Company and Outside The Box Capital Inc.](https://www.sec.gov/Archives/edgar/data/1837254/000121390025075072/ea025255301ex10-25_function.htm) |
| 10.26\*\*\* | [Escrow Agreement, dated August 6, 2025](http://www.sec.gov/Archives/edgar/data/1837254/000121390025084203/ea025559001ex10-26_function.htm) |
| 10.27\*\*\* | [Amendment to the Placement Agency Agreement](http://www.sec.gov/Archives/edgar/data/1837254/000121390025084203/ea025559001ex10-27_function.htm) |
| 10.28\*\*\* | [Eighth Amended Forbearance](http://www.sec.gov/Archives/edgar/data/1837254/000121390025084203/ea025559001ex10-28_function.htm) |
| 10.29\*\*\* | [Form of Amendment to Securities Purchase Agreement](https://www.sec.gov/Archives/edgar/data/1837254/000121390025089355/ea025801401ex10-29_function.htm) |
| 10.30\* | [Ninth Amended Forbearance](ea025978501ex10-30_function.htm) |
| 23.1\*\*\* | [Consent of TAAD LLP](https://www.sec.gov/Archives/edgar/data/1837254/000121390025089355/ea025801401ex23-1_function.htm) |
| 23.2\* | [Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)](ea025978501ex5-1_function.htm) |
| 99.1\*\*\* | [Audit Committee Charter](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex99-1_function.htm) |
| 99.2\*\*\* | [Compensation Committee Charter](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex99-2_function.htm) |
| 99.3\*\*\* | [Nominating and Corporate Governance Committee Charter](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex99-3_function.htm) |
| 99.4\*\*\* | [Consent of Girard Smith as Director Nominee](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex99-4_function.htm) |
| 99.5\*\*\* | [Consent of Steven Rossi as Director Nominee](https://www.sec.gov/Archives/edgar/data/1837254/000121390025089355/ea025801401ex99-5_function.htm) |
| 99.6\*\*\* | [Consent of Lourdes Felix as Director Nominee](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex99-6_function.htm) |
| 99.7\*\*\* | [Executive Compensation Clawback Policy](http://www.sec.gov/Archives/edgar/data/1837254/000121390025007595/ea022831201ex99-7_function.htm) |
| 107\*\*\* | [Filing Fee Table](https://www.sec.gov/Archives/edgar/data/1837254/000121390025075072/ea025255301ex-fee_function.htm) |

---

\*\*\* Previously filed. <br> \*\* To be filed by Amendment <br> \* Filed herewith

(b) Financial Statement Schedules.

All financial statement schedules are omitted because the information called for is not required or is shown either in the financial statements or in the notes thereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized on October 1, 2025.

---

| | |
|:---|:---|
| **Functional Brands Inc.** | **Functional Brands Inc.** |
| By: | /s/ Eric Gripentrog |
|  | Eric Gripentrog |
|  | Chief Executive Officer and Director |

---

---

| | | |
|:---|:---|:---|
| **SIGNATURE** | **TITLE** | **DATE** |
| /s/ Eric Gripentrog | Chief Executive Officer and Director | October 1, 2025 |
| Eric Gripentrog | (Principal Executive Officer) |  |
| /s/ Tariq Rahim | Chief Financial Officer, and Director | October 1, 2025 |
| Tariq Rahim | (Principal Financial & Accounting Officer) |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

October 1, 2025

**VIA ELECTRONIC TRANSMISSION**

Functional Brands Inc.

6400 SW Rosewood Street

Lake Oswego, Oregon 97035

**Re: Registration Statement on Form S-1**

Ladies and Gentlemen:

We have acted as counsel to Functional Brands, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing of a Registration Statement on Form S-1, as amended from time to time (the "Registration Statement") with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), including a related prospectus filed with the Registration Statement (the "Prospectus") relating to the registration for resale of up to 17,883,693 shares of the Company's common stock, par value $0.00001, by certain selling stockholders (the "Resale Shares"). We understand that the Resale Shares are to be sold, as described in the Registration Statement.

We have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company and public officials, and other documents as we have deemed relevant and necessary as a basis for the opinion hereinafter expressed.

In such examination and in rendering the opinion expressed below, we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us, (ii) the legal capacity and authority of all persons or entities (other than the Company) executing all agreements, instruments, corporate records, certificates and other documents submitted to us, (iii) the authenticity and completeness of all agreements, instruments, corporate records, certificates and other documents submitted to us as originals, (iv) that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other copies conform to authentic originals thereof, and that such originals are authentic and complete, (v) the due authorization, execution and delivery of all agreements, instruments, certificates and other documents by all parties thereto (other than the Company), (vi) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for the purposes of this opinion set forth below are true and correct, and (vii) that the officers and directors of the Company have properly exercised their fiduciary duties. We also have made such further legal and factual examinations and investigations as we deemed necessary for purposes of expressing the opinion set forth herein and have obtained from the officers of the Company certificates as to certain factual matters necessary for the purpose of this opinion and, insofar as this opinion is based on such matters of fact, we have relied solely on such certificates without independent investigation.

Based on the foregoing, and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that the issuance and sale of the Resale Shares has been duly authorized by all necessary corporate action on the part of the Company and, when issued and sold in the manner described in the Registration Statement, the Resale Shares, will be validly issued, fully paid and non-assessable.

Without limiting any of the other limitations, exceptions and qualifications stated elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the corporate laws of the State of Delaware and the laws of the State of New York, as currently in effect (based solely upon our review of a standard compilation thereof). We express no opinion as to whether the laws of any jurisdiction are applicable to the subject matter hereof. This opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company or the Resale Shares. We are not rendering any opinion as to compliance with any federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof. This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this opinion letter.

We hereby consent to the filing of this opinion as Exhibits 5.1 and 23.2 to the Registration Statement and to the reference to our firm under "Legal Matters" in the related Prospectus. In giving the foregoing consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Securities and Exchange Commission.

---

| |
|:---|
| Very truly yours, |
| */s/ Sichenzia Ross Ference Carmel LLP* |

---

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036

T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW

## Exhibit 10.30

**Exhibit 10.30**

**NINTH AMENDED FORBEARANCE AGREEMENT**

This Amended Forbearance Agreement ("Agreement"), effective as of September 30, 2025, is made by and among HTO Nevada Inc. ("HTO Nevada "), HTO Holdings Inc. ("HTO Holdings"), and Functional Brands Inc., ("Functional Brands"), aka HT Naturals, Inc., a Delaware Corporation, ("Functional Brands"), jointly and severally ("Purchaser") and Kirkman Laboratories, Inc. ("Kirkman Lab"), Kirkman Group International, Inc. ("Kirkman International" and together with Kirkman Lab referred to as the "Kirkman Parties"), Kirkman Group, Inc. ("Kirkman Group" and together with the Kirkman Parties referred to as "Sellers"), and David K. Humphrey ("Humphrey") and collectively with Purchaser and the Sellers as the "Parties" or individually as a "Party").

**RECITALS**

WHEREAS, the Parties entered into that certain Asset Purchase Agreement dated as of June 28, 2019 (the "Original Asset Purchase Agreement), that certain Amendment No. 1 to the Asset Purchase Agreement dated November 30, 2021 (the "First Amendment"), and that certain Amendment No. 2 to the Asset Purchase Agreement dated May 16, 2022 (the "Second Amendment"), Amendment No. 3 to APA dated August 1, 2024, Amendment No. 4 dated September 24, 2024; (the Original Asset Purchase Agreement, First Amendment, Second Amendment, Third Amendment, Fourth Amendment collectively, the "Asset Purchase Agreement"), and various associated agreements (the "Collateral Agreements"), in which, among other things, Sellers sold to Purchaser various assets, including certain Intangible Assets including Intellectual Property;

WHEREAS, under the Original Asset Purchase Agreement, Purchaser and HTO Holdings Inc. were to make certain payments toward the purchase price set forth in the Asset Purchase Agreement;

WHEREAS, under the First Amendment, the Parties agreed to amend the Asset Purchase Agreement's payment schedule;

WHEREAS, under the Second Amendment, the Parties made corrections to the schedules and exhibits to the Asset Purchase Agreement and the Collateral Agreements listing and relating to the Intellectual Property;

WHEREAS, under the Third Amendment, the Parties made corrections to the schedules and exhibits to the Asset Purchase Agreement and the Collateral Agreements listing and relating to the Intellectual Property;

WHEREAS, under the Fourth Amendment, the Parties made corrections to the schedules and exhibits to the Asset Purchase Agreement and the Collateral Agreements listing and relating to the Intellectual Property;

WHEREAS, under a Letter Agreement dated May 31, 2022, Purchaser has paid Purity Labs, Inc. the total sum of $100,000 (the "Purity Payment") and has Humphrey the total sum of $250,000 (the "Humphrey Payment", and together with the Purity Payment, the "Immediate Payments");

1 – NINTH AMENDED FORBEARANCE AGREEMENT

WHEREAS, the Parties executed a Forbearance Agreement (the "Forbearance Agreement") extending the payment due under the Asset Purchase Agreement to August 31, 2022.

WHEREAS, Purchaser is in default of the August 31, 2022 payment due under the Forbearance Agreement and (the "Obligations");

WHEREAS, Purchaser has paid Sellers $65,000 due under the Asset Purchase Agreement in September 2022.

WHEREAS, the Parties executed a First Amended Forbearance Agreement on or about December 27, 2022, under which Purchaser has made the following payments: $250,000 and $15,000 interest per month for each month between September and December 2023, inclusive, and a $7,500 payment in January 2024;

WHEREAS, HTO Nevada Inc. was acquired by Functional Brands Inc. on or about May 19, 2023, as part of a corporate restructuring; and, is now a wholly owned subsidiary of Functional Brands Inc. In this transaction, HTO Holdings Inc. transferred all outstanding shares of HTO Nevada Inc. to Functional Brands Inc. a wholly owned subsidiary.

WHEREAS, the Parties executed a Second Amended Forbearance Agreement on or about March 1, 2024, under which the Purchaser has made the following payments: $130,000 and $20,000 per month ($15,000 interest and $5,000 principal) for each month beginning March 2024 through July 2024;

WHEREAS, the Parties executed a Third Amended Forbearance Agreement on or about August 1, 2024, under which the Purchaser has made the following payments: $20,000 per month ($15,000 interest and $5,000 principal) for each month beginning August 2024 through September 2024; and an additional $20,000 principal payments in August.

WHEREAS, the Parties executed a Fourth Amended Forbearance Agreement on or about September 24, 2024, under which the Purchaser has made the following payments: $20,000 per month ($15,000 interest and $5,000 principal) for each month beginning October 1, 2024 through December 31, 2024; and an additional $20,000 principal payments in October, November and December, 2024.

WHEREAS, the Parties executed a Fifth Amended Forbearance Agreement on or about December 31, 2024, under which the Purchaser has made the following payments: $20,000 per month ($15,000 interest and $5,000 principal) for January and February 2025.

WHEREAS, the Parties informally extended the Fifth Amended Forbearance Agreement providing for payments of $50,000 on or about March 5, 2025 and $50,000 on or about April 1, 2025 and $50,000 on or about May 1, 2025.

WHEREAS, the Parties extended the Sixth Amended Forbearance Agreement providing for payments of $30,000 on or about June 1, 2025 and $30,000 on or about July 1, 2025.

WHEREAS, the Parties extended the Seventh Amended Forbearance Agreement providing for payments of $30,000 on or about August 1, 2025.

"WHEREAS, Purchaser has made the $30,000 payment on or about September 1, 2025, which was applied as an interest-only payment pursuant to the Eighth Amended Forbearance Agreement."

**"WHEREAS, the Parties have extended this Ninth Amended Forbearance Agreement providing for payments of $30,000 on or about October 1, 2025 ($20,000 interest / $10,000 principal), and $15,000 on or about November 1, 2025 ($10,000 interest / $5,000 principal), with all other terms and conditions remaining unchanged.**

2 – NINTH AMENDED FORBEARANCE AGREEMENT

**WHEREAS, the balance due as of the date of this Ninth Amended Forbearance Agreement is $2,227,366.00.**

WHEREAS, Purchaser and HTO Holdings have requested Sellers to forbear from exercising their rights and remedies under the Asset Purchase Agreement and Forbearance Agreement; and

WHEREAS, Sellers are willing to forbear from exercising such rights and remedies for a limited period of time, provided that Purchaser and HTO Holdings complies with the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Purchaser Acknowledgments</u>. Purchaser acknowledges and agrees that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.1 <u>Recitals</u>. The above recitals are true and correct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <u>Transaction Documents</u>. The Asset Purchase Agreement, Collateral Agreements, Forbearance Agreement, and all other agreements, instruments, and other documents executed in connection with or relating to the Asset Purchase Agreement (the "Transaction Documents") are legal, valid, binding, and enforceable against Purchaser in accordance with their terms. Except as otherwise set forth herein, the terms of the Transaction Documents remain unchanged. Undefined capitalized terms used herein shall have the meanings ascribed thereto in the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <u>Default</u>. The following Event of Default has occurred and is continuing under the Transaction Documents:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Failure to make timely payments due under the Asset Purchase Agreement, the amendments thereto and subsequent Forbearance Agreements or payment in full, with a remaining balance due under the Asset Purchase Agreement and the Fifth Forbearance Agreement of $2,227,366.00 (the "Existing Default").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <u>Obligations</u>. The Obligations are not subject to any setoff, deduction, claim, counterclaim, or defenses of any kind or character whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <u>Collateral</u>. Purchaser represents that Sellers have valid, enforceable, and first position, perfected security interests in and to and liens under the Collateral Agreements, as to which there are no setoffs, deductions, claims, counterclaims, or defenses of any kind or character whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Consistent with that letter agreement dated May 31, 2022, Purchaser acknowledges and agrees that Sellers have had and continue to retain a security interest in and to all of Purchasers respective assets, including but not limited to any machinery, equipment, furniture, furnishings, tools, fixtures, parts, accessories, accounts , inventory, raw materials, work-in-progress, finished goods, cash, deposit accounts, investments, investment accounts, leasehold interests, permits, licenses, intellectual property, patents, patent applications, trademarks, service marks, copyrights, trade secrets, domain names, software, any other intellectual property rights, contracts, contract rights, rights under purchase orders, instruments, chattel paper, notes, drafts, any obligations for the payment of money arising out of the sale or lease of goods, any and all after acquired assets and any and all proceeds derived from the assets. Functional Brands Inc. acknowledges and agrees that pursuant to its purchase of all outstanding shares of HTO Nevada, Inc., that it acquired HTO Nevada, Inc. subject to Seller's security interest. To the extent necessary, Purchaser, jointly and severally, hereby grant Sellers a security interest in any and all collateral and assets set forth above and elsewhere in the Original Asset Purchase Agreement, Collateral Agreements, any and all Forbearance Agreements and this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Purchaser further hereby grants Sellers a ''lien'' on Purchaser's accounts receivable.

3 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <u>No Waiver of Default</u>. Neither this Agreement, nor any actions taken in accordance with this Agreement or the Transaction Documents, shall be construed as a waiver of or consent to the Existing Default or any other existing or future defaults under the Transaction Documents, as to which Sellers' rights shall remain reserved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 <u>Preservation of Rights and Remedies</u>. Upon expiration of the Forbearance Period (as defined below), all of Sellers' rights and remedies under the Transaction Documents and at law and in equity shall be available without restriction or modification, as if the forbearance had not occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <u>Purpose of Forbearance</u>. The purpose of this Agreement is to provide Purchaser with a period of time to cure the Existing Default.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <u>Request to Forbear</u>. Purchaser has requested Sellers' forbearance as provided herein, which shall inure to their direct and substantial benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. <u>Sellers Forbearance</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Forbearance Period</u>. Subject to compliance by Purchaser with the terms and conditions of this Agreement, Sellers hereby agree to forbear from exercising their rights and remedies against Purchaser under the Transaction Documents with respect to the Existing Default during the period (the "Forbearance Period") commencing on the Effective Date (as defined below) and ending on the earlier to occur of (i) November 15, 2025 and (ii) the date that any Forbearance Default (as defined below) occurs, upon which, Sellers' forbearance, as provided herein, shall immediately and automatically cease without any requirement of notice or further action by any party (the "Termination Date"). On and from the Termination Date, Sellers may, in their sole discretion, exercise any and all remedies available to them under the Transaction Documents that otherwise would be available only by reason of the occurrence of any Events of Default thereunder or the continuation of any Existing Default.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Extension of Forbearance Period</u>. In the sole and absolute discretion of Sellers and without obligation, after the Termination Date, Sellers may renew or extend the Forbearance Period, or grant additional forbearance periods.

4 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Scope of Forbearance</u>. During the Forbearance Period only, Sellers will not (i) accelerate the maturity of the Obligations or initiate proceedings to collect the Obligations; (ii) initiate or join in filing any involuntary bankruptcy petition with respect to Purchaser under the Bankruptcy Code, or otherwise file or participate in any insolvency, reorganization, moratorium, receivership, or other similar proceedings against Purchaser under the laws of the US; or (iii) repossess or dispose of any of the Collateral, through judicial proceedings or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Conditions Precedent</u>. This Agreement shall not become effective unless and until the date (the "Effective Date") that each of the following conditions shall have been satisfied in Sellers' sole and absolute discretion, unless waived in writing by Sellers:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Delivery of Certain Documents</u>. Purchaser shall deliver or cause to be delivered the following documents, each in substance and form acceptable to Sellers:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) a copy of this Agreement, duly executed by Purchaser;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) an updated Confession of Judgment executed by Purchaser, in the form attached hereto and incorporated herein by this reference as Appendix 3.l; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) such other documents as Sellers may request with respect to any matter relevant to this Agreement or the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Payments During Forbearance Period</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1 <u>Interest-Only Payments</u>. Purchaser has already paid a $15,000 interest payment for February 2024 and March 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2 <u>Payments of Interest and Principal.</u> Purchaser has already made payments of $20,000 per month, due the first day of each of April, May, June, July, August, September 2024, with $15,000 of each payment allocated to interest and the remaining $5,000 of each payment allocated to principal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.3 <u>Payments of Interest and Principal.</u> Purchaser has also made payments of $20,000 per month for October, November and December, 2024, with $15,000 of each payment allocated to interest and the remaining $5,000 of each payment allocated to principal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.4 <u>Additional Payments.</u> Purchaser has already made a principal payment of $130,000 against the remaining balance over the course of 3 payments. First payment occurred on March 15, 2024 of $45,000, and subsequent payments occurred for $40,000 on April 15, 2024 and $45,000 on May 15, 2024 to satisfy the $130,000 principle payment. Purchaser made another $20,000 payment towards principal on August 15, 2024, October 15, 2024, November 15, 2024 and December 15, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.5 <u>Additional Principal & Interest Payment:</u> The Purchaser has also made payments of $20,000 payment for January and February 2025, with $15,000 of each payment allocated to interest and the remaining $5,000 of each payment allocated to principal.

5 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.6 The Purchaser has made payments of $50,000 on March 5, 2025, $50,000 on April 1, 2025 and $50,000 on May 1, 2025, with $15,000 of each payment allocated to interest and the remaining $35,000 of each payment allocated to principal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.7 The Purchaser has made payments in the amounts of $30,000 on or about June 1, 2025, and $30,000 payment on or about July 1, 2025. $30,000 of each payment was designated as an interest only payment, and none to principal, regardless of rate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.8 The purchaser already made a payment of $30,000 on or about August 1, 2025 and this payment was designated as interest only payment, and non to principal, regardless of rate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.9 "Purchaser acknowledges that the $30,000 payment due on or about September 1, 2025 has been made and applied entirely to interest."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.10 Purchasers new obligations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.11 $30,000 due October 1, 2025 ($20,000 to interest / $10,000 to principal)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.12 $15,000 due November 1, 2025 ($10,000 to interest / $5,000 to principal).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.13 If any payment is partial or pro rata, amounts shall first be allocated to interest for the applicable period, with the balance applied to principal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.14 <u>Balance Due Payment.</u> As of September 1, 2025, the balance due and owing is $2,227,366.00 (the "Balance"). Purchaser shall pay Seller the Balance by wire transfer on or before November 15, 2025, subject to reduction for any principal payments actually made pursuant to Section [Payments During Forbearance Period]. Any such principal payments shall reduce the Balance on a dollar-for-dollar basis as and when received.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.15 The Purchaser's payment of the Balance Due Payment under this Agreement shall fully satisfy the Obligations and cure the Existing Default. Payment of the Balance Due Payment shall not act as a cure to any other default whether known or unknown at the time of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.16 Time is of the Essence as to all payments due and owing.

6 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Representations and Warranties</u>. Purchaser represents and warrants as to itself that all representations and warranties relating to it contained in the Transaction Documents are true and correct as of the Effective Date, except to the extent that such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects as of such earlier date. Purchaser further represents and warrants to Sellers as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Authorization</u>. The execution, delivery, and performance of this Agreement are within its corporate power and have been duly authorized by all necessary corporate action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Enforceability</u>. This Agreement constitutes a valid and legally binding Agreement enforceable against Purchaser in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, and similar laws affecting creditors' rights generally and to general principles of equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <u>No Violation</u>. The execution, delivery, and performance of this Agreement do not and will not (i) violate any law, regulation, or court order to which Purchaser is subject; (ii) conflict with Purchaser's organizational documents; or (iii) result in the creation or imposition of any lien, security interest, or encumbrance on any property of Purchaser, or any of its subsidiaries, whether now owned or hereafter acquired, other than liens in favor of Sellers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <u>No Litigation</u>. No action, suit, litigation, investigation, or proceeding of or before any arbitrator or governmental authority is pending or, to the knowledge of Purchaser, threatened by or against or affecting Purchaser or against any of its property or assets with respect to any of the Transaction Documents or any of the transactions contemplated hereby or thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <u>No Change</u>. Except as previously disclosed to Sellers, there has been no material adverse change in the business, operations, assets, or financial or other condition of the Purchaser and its subsidiaries taken as a whole.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 <u>Accuracy of Information</u>. All information provided by Purchaser or any of its agents, is true, correct, and complete in all material respects, as of the date provided and does not contain any untrue statements of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7 <u>Advice of Counsel</u>. Purchaser has freely and voluntarily entered into this Agreement with the advice of legal counsel of its choosing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Covenants</u>. In addition, in order to induce Sellers to forbear from the exercise of their rights and remedies as set forth above, Purchaser hereby covenants and agrees that at all times during the Forbearance Period, unless Sellers otherwise consent in writing, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Compliance with Transaction Documents</u>. Purchaser shall continue to perform and observe all covenants, terms, and conditions, and other obligations contained in all of the Transaction Documents and this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Sale of Assets</u>. Purchaser shall not sell, convey, transfer, assign, lease, abandon, or otherwise dispose of any of its assets, tangible or intangible (including but not limited to sale, assignment, discount, or other disposition of accounts, contract rights, or general intangibles with or without recourse), without Sellers' prior written consent. If Sellers grant written consent, Purchaser shall cause Purchaser or other transferee to pay all proceeds of such disposition directly to Sellers for application to the Obligations.

7 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <u>Perfection of Sellers' Liens</u>. Purchaser shall execute and deliver to Sellers such documents and take such actions as Sellers reasonably deem necessary or advisable to perfect or protect the Sellers' security interests, mortgages, or liens granted by Purchaser to Sellers under any of the Transaction Documents or this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <u>Other Financial Information</u>. Purchaser shall promptly provide to Sellers such other financial information as Sellers may reasonably request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <u>Further Assurances</u>. Promptly upon the request of Sellers, Purchaser shall take any and all reasonable actions, and execute and deliver additional documents, that relate to this Agreement and the transactions contemplated herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Release of Claims and Waiver of Defenses</u>. In further consideration of Sellers' execution of this Agreement, Purchaser, on behalf of itself and its successors, assigns, parents, subsidiaries, affiliates, officers, directors, employees, agents, and attorneys hereby forever, fully, unconditionally and irrevocably waives and releases Sellers and their successors, assigns, parents, subsidiaries, affiliates, officers, directors, employees, attorneys, and agents (collectively, the "Releasees") from any and all claims, liabilities, obligations, debts, causes of action (whether at law or in equity or otherwise), defenses, counterclaims, setoffs, of any kind, whether known or unknown, whether liquidated or unliquidated, matured or unmatured, fixed or contingent, directly or indirectly arising out of, connected with, resulting from, or related to any act or omission by any Sellers or any other Releasee with respect to the Transaction Documents and any Collateral, other than any Sellers' or any Releasee's willful acts or omissions, on or before the date of this Agreement (collectively, the "Claims"). Purchaser further agrees that Purchaser shall not commence, institute, or prosecute any lawsuit, action, or other proceeding, whether judicial, administrative, or otherwise, to collect or enforce any Claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Indemnification</u>. Purchaser hereby expressly acknowledges, agrees, and reaffirms its indemnification obligations to Sellers and the other Indemnified Parties set forth in the Transaction Documents. Purchaser further acknowledges, agrees, and reaffirms that all such indemnification obligations shall survive the expiration of the Forbearance Period and the termination of this Agreement, the Transaction Documents, and the payment in full of the Obligations. Notwithstanding the foregoing, such indemnity shall not be available to the extent that such claims, damages, losses, liabilities, or related expenses result solely from a Lender's or other Indemnified Party's gross negligence or willful misconduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Events of Default</u>. The occurrence of one or more of the following shall constitute a "Forbearance Default" under this Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 Purchaser shall fail to abide by or observe any term, condition, covenant, or other provision contained in this Agreement or any document related to or executed in connection with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 A default or event of default shall occur under any Transaction Document or any document related to or executed in connection with this Agreement or any of the Transaction Documents (other than the Existing Default).

8 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.3 Purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) becomes insolvent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) (i) commences any case, proceeding, or other action under any existing or future requirement of law relating to bankruptcy, insolvency, reorganization, or other relief of debtors, seeking (A) to have an order for relief entered with respect to it, or (B) to adjudicate it as bankrupt or insolvent, or (C) reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition, or other relief with respect to it or its debts, or (D) appointment of a receiver, trustee, custodian, conservator, or other similar official for it or for all or any substantial part of its assets, or (ii) makes a general assignment for the benefit of its creditors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) has commenced against it in a court of competent jurisdiction any case, proceeding, or other action of a nature referred to in clause (c) above which (i) results in the entry of an order for relief or any such adjudication or appointment or (ii) remains undismissed, undischarged, unstayed, or unbonded for 30 days; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (e) ceases to conduct business in the ordinary course.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4 Any representation or warranty of Purchaser made herein shall be false, misleading, or incorrect in any material respect when made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5 Purchaser takes an action, or any event or condition occurs or exists, which Sellers reasonably believe in good faith is inconsistent in any material respect with any provision of this Agreement, or impairs, or is likely to impair, the prospect of payment or performance by Purchaser of its obligations under this Agreement or any of the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Remedies</u>. Immediately upon the occurrence of a Forbearance Default, Sellers may pursue any and all of the remedies outlined below or elsewhere provided in this Agreement. No remedy granted herein to Sellers is intended to be exclusive of any other available remedy or remedies. Each and every remedy granted herein is cumulative and in addition to every other remedy given under this Agreement, now or hereafter existing at law or in equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 The Forbearance Period shall immediately and automatically cease without notice or further action without notice to, or action by, any party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 Sellers may, in Seller's sole discretion, enter the Confession of Judgment described in Section 3.1(b) as evidence of Sellers' rights as a secured creditor and proof of Purchaser's default under the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 Sellers shall be entitled to exercise any or all of their rights and remedies under the Transaction Documents, this Agreement, or any stipulations or other documents executed in connection with or related to this Agreement or any of the Transaction Documents, or applicable law, including, without limitation, the appointment of a receiver.

9 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 Purchaser shall cooperate with Sellers' repossession of all of Purchaser's personal property Collateral, which Purchaser shall immediately surrender to Sellers upon Sellers' request, at the time and place designated by Sellers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5 Sellers may, in their sole discretion, commence foreclosure actions with respect to any real property Collateral and replevin actions with respect to any of the other Collateral.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6 Sellers may set off or apply to the payment of any or all of the Obligations, any deposit balances, any or all of the Collateral or proceeds thereof, or other money now or hereafter owed Sellers by Purchaser.

Sellers may, in Sellers sole discretion, pursue any and all remedies provided ORS Chapter 79, including without limitation any and all self-help remedies therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. Foreclosure Rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 Pursuant to Section 10.7 above, Purchasers agree that Sellers' foreclosure remedies include, but are not limited to a decree and judgment:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) granting Sellers immediate possession of the Collateral described above;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) rights and remedies of strict foreclosure of all Collateral;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) ordering Purchasers to surrender the Collateral to Sellers within ten (10) days of the date of the Confession of Judgment or other judgment is entered;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) authorizing Sellers to foreclose their security interests in the Collateral and:

● sell the same in a commercially reasonable manner as permitted by law and apply the proceeds of any sale of the Collateral to the satisfaction of the Confession of Judgment, including all lawful expenses of collection and sale, with any deficiency or surplus to be handled in accordance with applicable law, and/or

● in Sellers sole discretion retain, possess, and utilize the Collateral for the purposes of continuing its operations or business functions, including without limitation, assuming control of ongoing customer contracts, sales, vendor relationships, managing employees and other activities necessary to maintain business continuity, free and clear of any claim, lien, or right of redemption of the Purchasers and all persons claiming by, through, or under the Purchasers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2 The Purchasers agree and acknowledge retention and continued use of the collateral by Sellers shall not constitute a breach of duty, nor be construed as a waiver of Sellers' rights under the Confession of Judgment or under applicable law. The Purchasers agree and acknowledge that continuity of operations through retention or acquisition of the collateral is commercially reasonable, promotes mitigation of loss, and is in the interest of judicial efficiency and creditor recovery. The Purchasers agree that net income earned pursuant to business continuity operations shall be applied to the Confession of Judgment.

10 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3 **No Obligation to Sell Collateral.** Sellers are under no obligation to sell the Collateral to satisfy the debt. Sellers may continue to operate the business in its current form, using the foreclosed assets to generate net revenue to repay the outstanding balance owed by Purchasers under the Confession of Judgment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.4 **Valuation of Foreclosed Collateral for Repayment.** In the event Purchaser elects to continue operations and the business in lieu of selling the Collateral, the value of the business may be determined by a qualified third-party appraiser appointed by the Sellers, provided that the selection of the appraiser is commercially reasonable. The appraiser shall establish the fair market value of the business, and its assets based on a forced liquidation value. This appraised value shall be applied towards the satisfaction of the debt owed by Purchasers. If the appraised value exceeds the amount owed, the debt shall be considered satisfied, and no further action shall be required by Purchasers. If the appraised value is less than the amount owed, Sellers may continue to operate the business and generate revenue from its operations whereupon net revenue shall be accepted in lieu of the balance of the debt. Purchasers' rights to any revenue, surplus, receipts or proceeds from business operations, including profits generated beyond the liquidation value, are hereby deemed to be fully and permanently extinguished.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.5 **Waiver of Revenue and Deficit.** In the event Purchaser elects to continue operations and the business in lieu of selling the Collateral, Sellers shall retain all revenue generated from the operation of the business beyond the appraised liquidation value of the assets. Purchasers shall have no claim or entitlement to any revenue generated by the business. In exchange for Purchasers waiver, Sellers agree to excuse any remaining deficit or shortfall between the liquidation value and the total amount of the Confession of Judgment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.6 **Optional Sale or Assignment of Business.** While Sellers are not required to sell the Collateral, they shall retain the option to sell all or a portion of the Collateral at their sole discretion. Any decision to sell or assign the business or its Collateral to a third party shall be entirely at the discretion of Sellers, but is not necessary for the satisfaction of the debt.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.7 **Optional Public Sale:** In the event Sellers chooses to sell all or a portion of the Collateral by public sale, which it has sole discretion to do, the Collateral will be sold pursuant to Article 9 of the Uniform Commercial Code. The proceeds of a sale will be applied in the following order: the cost and expense of sale, and then toward the satisfaction of the debt plus costs, disbursements, and reasonable attorney fees as allowed Sellers by a court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.8 From the day of any sale, strict foreclosure or other disposition of the collateral allowed by the APA, Security Agreements, Forbearance Agreements or the Confession of Judgment by Sellers all Purchasers are forever foreclosed of any and all right, title, lien, interest, or claim in or to the Assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.9 Upon any foreclosure by Secured Party pursuant to the Confession of Judgment dated May 28, 2025 and without the necessity of appraisal, auction, or further conveyance, all right, title and interest of Company in and to the Trademarks listed on Schedule A, together with all associated goodwill, shall immediately and automatically vest in Secured Party. The parties acknowledge and agree that such vesting shall occur solely upon foreclosure, and not before, and that until such time Company shall remain the owner of record with full right to use, register, and maintain the Trademarks in the ordinary course of business.

11 – NINTH AMENDED FORBEARANCE AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Miscellaneous</u>.

<u>Additional Information</u>. Purchaser shall provide to Sellers such additional information regarding Purchaser as Sellers may reasonably request in order to assure or demonstrate compliance with applicable securities law or other laws or for any other legitimate purpose claims and losses arising out of or related to this Agreement. Nothing in this Agreement shall be deemed a waiver, modification, or release of any rights or remedies available to Sellers, including without limitation all rights under the existing Confession of Judgment, which remains in full force and effect. All such rights are expressly reserved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 <u>Governing Law</u>. This Agreement is governed by the laws of the state of Oregon, without giving effect to any conflict-of-law principle that would result in the laws of any other jurisdiction governing this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2 <u>Attorney Fees</u>. If any suit or action is instituted arising out of or related to this Agreement, including but not limited to any proceeding brought under the United States Bankruptcy Code, the prevailing party on a claim will be entitled to recover with respect to the claim, in addition to any other relief awarded, the prevailing party's reasonable attorney's fees and other fees, costs, and expenses of every kind, including but not limited to the costs and disbursements specified in ORCP 68 A(2), incurred in connection with the arbitration, action, suit, or proceeding, any appeal or petition for review, the collection of any award, or the enforcement of any order, as determined by the arbitrator or court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.3 <u>Survival</u>. The representations, warranties, covenants and agreements made herein shall survive the Forbearance Period for a period of 1 year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.4 <u>Successors and Assigns</u>. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.5 <u>Entire Agreement; Amendment</u>. This Agreement, together with the exhibits and other documents delivered pursuant hereto, constitute the entire agreement between the parties with regard to the subject matter hereof. This Agreement or any term hereof may be amended, waived, discharged or terminated solely by a written instrument signed by the Sellers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.6 <u>Severability</u>. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.7 <u>Titles and Subtitles</u>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.8 <u>Expenses</u>. Purchaser shall pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.9 <u>Interpretation</u>. The words "will" and "shall" have the same meaning in this Agreement. References in this Agreement to "includes" or "including" mean "including without limitation." The word "or" is not exclusive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.10 <u>Counterparts; Delivery</u>. This Agreement may be (a) executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument, and (b) delivered by transfer of an originally signed document by facsimile, e-mail or other electronic means, any of which will be as fully binding as delivery of an original document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.11 <u>Confidentiality</u>. Purchaser acknowledges that the information provided to it regarding the Sellers is confidential and non-public. Purchaser agrees that all of the information will be kept in confidence and will be neither used to its personal benefit nor disclosed to any third party, but this obligation does not apply to any such information that (a) is part of public knowledge on the date of this Agreement, (b) becomes a part of public knowledge by means other than a breach of this provision, or (c) is received from a third party who did not disclose such information in violation of any obligation of confidentiality he, she or it may have to Sellers.

[SIGNATURE PAGES TO FOLLOW]

12 – NINTH AMENDED FORBEARANCE AGREEMENT

**IN WITNESS WHEREOF, THE PARTIES HERETO HAVE EXECUTED THIS AGREEMENT AS OF THE DATE FIRST ABOVE WRITTEN.**

---

| | | |
|:---|:---|:---|
| **SELLERS:** | KIRKMAN GROUP, INC. | KIRKMAN GROUP, INC. |
|  | By: |  |
|  | Name: | David K. Humphrey |
|  | Title: | President |
|  | KIRKMAN LABORATORIES, INC. | KIRKMAN LABORATORIES, INC. |
|  | By: |  |
|  | Name: | David K. Humphrey |
|  | Title: | President |
|  | KIRKMAN GROUP INTERNATIONAL, INC. | KIRKMAN GROUP INTERNATIONAL, INC. |
|  | By: |  |
|  | Name: | David K. Humphrey |
|  | Title: | President |
| **SELLERS' OWNER:** | DAVID K. HUMPHREY | DAVID K. HUMPHREY |
|  | By: |  |
| **SELLERS' AGENT:** | DAVID K. HUMPHREY | DAVID K. HUMPHREY |
|  | By: |  |
| **PURCHASER:** | HTO NEVADA INC. | HTO NEVADA INC. |
|  | By: |  |
|  | Name: | Eric Gripentrog |
|  | Title: | Chief Executive Officer |

---

13 – NINTH AMENDED FORBEARANCE AGREEMENT

---

| | | |
|:---|:---|:---|
| **HTO HOLDINGS INC.:** | HTO HOLDINGS INC. | HTO HOLDINGS INC. |
|  | By: |  |
|  | Name: | Eric Gripentrog |
|  | Title: | Chief Executive Officer |
| **FUNCTIONAL BRANDS INC:** | FUNCTIONAL BRANDS INC. | FUNCTIONAL BRANDS INC. |
|  | By: |  |
|  | Name: | Eric Gripentrog |
|  | Title: | Chief Executive Officer |

---

Hemptown Organics Corp. and Hemptown USA, LLC., as affiliated entities of Purchasers HTO Nevada, HTO Holdings and Functional Brands, hereby consent, approve and ratify this Ninth Amended Forbearance Agreement, and agree to be bound by the terms herein; and that sufficient consideration has been received in exchange for their agreement.

---

| | | |
|:---|:---|:---|
| **HEMPTOWN ORGANICS CORP.:** | HEMPTOWN ORGANICS CORP. | HEMPTOWN ORGANICS CORP. |
|  | By: |  |
|  | Name: | Eric Gripentrog |
|  | Title: | Chief Executive Officer |
| **HEMPTOWN USA, LLC:** | HEMPTOWN USA, LLC | HEMPTOWN USA, LLC |
|  | By: |  |
|  | Name: | Eric Gripentrog |
|  | Title: | Chief Executive Officer |

---

14 – NINTH AMENDED FORBEARANCE AGREEMENT